09.19.25 -- STREAM Edition: CDMO Hunger Games And The State Of Biotech

Succeed in combination product development by understanding the risk factors that may arise and implementing mitigation strategies that will streamline the device development process.

Dr. Eisner explains how Vir’s Technology’s pivot from infectious disease to include oncology is more substantial than a large company reshuffling its portfolio, highlighting the thematic connection through the immune system and the foundational role of antibody engineering at Vir.

Discover how to maximize drug product recovery with an end-to-end fill-finish solution. Get excellent integrity assurance and exceptional lead times for your critical processes.

 Biotech leader Nicole Paulk, Ph.D., joins “Better Biopharma” to discuss Siren Biotechnology’s switch from plasmids to producer cell lines, CGT funding challenges, and the competition that determined which CDMO won Siren’s business.

Tech Talks explore ADC development innovations, including integrated supply chains, seamless pilot-to-GMP scale-ups, and advanced process analytical technology (PAT).

Current GLP-1 therapies have been highly successful, but significant unmet needs in obesity treatment remain, including a substantial number of patients who cannot tolerate the side effects. Additionally, the weight loss achieved with GLP-1s varies widely, so improving the efficacy of these drugs to achieve greater weight loss is still a major goal.